The authoritative source for research information and outputs is Elsevier Scopus, with researcher profile verification from the Deanship of Scientific Research.
المخرجات
Research outputs
Articles, reviews, conference papers and book chapters, indexed by DOI and linked to University researchers.
International Journal of Polymeric Materials · vol. 75 (8) · 835-858
Folate-conjugated chitosan nanoparticles represent a promising advancement in targeted drug delivery, offering enhanced specificity, biocompatibility, and controlled release profiles. Chitosan, a versatile biopolymer, provides a stable platform for nanoparticle synthesis, while folate conjugation enables selective targeting of folate receptors, which are overexpressed in various cancers and inflammatory diseases. This review explores the structural and functional properties of chitosan, mechanisms of folate receptor-mediated endocytosis, and innovative strategies for nanoparticle synthesis and functionalization. The review entails key formulation techniques, including nanoprecipitation, ionic gelation, and spray drying, alongside characterization methods essential for optimizing therapeutic efficacy. The biomedical applications of Folate-conjugated chitosan nanoparticles are highlighted in cancer therapy, gene delivery, and anti-inflammatory treatments, with an emphasis on emerging trends such as CRISPR-based targeting and dual-ligand strategies. This review critically examines the existing challenges and explores future directions, highlighting the promising role of folate-conjugated chitosan nanoparticles in the evolution of precision medicine.
targeted drug deliveryfolate receptorreceptor-mediated endocytosisnanoprecipitation
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), originally developed as antidiabetic agents, have emerged as candidate disease-modifying therapies for Parkinson’s disease (PD) and Alzheimer’s disease (AD), reflecting the widespread expression of GLP-1 receptors across neurons, glia, and the cerebral vasculature. This narrative review synthesizes mechanistic, clinical trial, and biomarker evidence for GLP-1 RAs in PD and AD, based on a literature search of PubMed, Embase, Scopus, and Web of Science, with ClinicalTrials.gov searched separately for trial protocols and results, through May 2026. Preclinical data implicate GLP-1 receptor agonism in anti-neuroinflammatory signaling, mitochondrial preservation, autophagy and proteostasis enhancement, anti-apoptotic effects, synaptic plasticity, cerebrovascular protection, and glymphatic clearance. Clinical evidence in PD is mixed and agent- and formulation-dependent: the phase II Exenatide-PD trial reported a motor benefit that persisted after washout (∼3.5-point between-group difference in MDS-UPDRS Part III), and the phase II LIXIPARK trial (lixisenatide) reported a significant 3.08-point between-group difference (95% CI 0.86–5.30; p = 0.007) favoring lixisenatide, whereas the larger, longer phase III Exenatide-PD3 trial, using an extended-release weekly formulation, found no significant effect on the same endpoint (adjusted coefficient 0.92; 95% CI −1.56 to 3.39; p = 0.47); oral semaglutide is under investigation in the ongoing phase II MOST-ABLE trial. In AD, the phase IIb liraglutide (ELAD) trial did not achieve statistical benefit on either its primary imaging endpoint (cerebral glucose metabolic rate; p = 0.14) or on most secondary cognitive measures, and the phase III semaglutide trials EVOKE and EVOKE+ did not meet their primary CDR-SB endpoint (estimated difference −0.08, 95% CI −0.35 to 0.20, p = 0.57 in EVOKE; 0.10, 95% CI −0.17 to 0.38, p = 0.46 in EVOKE+), despite biomarker signals including reductions in cerebrospinal fluid tau species and inflammatory markers. Comparative pharmacology reveals substantial heterogeneity in central nervous system penetration, receptor engagement, and systemic bioavailability across exenatide, liraglutide, semaglutide, and the imbalanced GLP-1/GIP co-agonist tirzepatide, complicating cross-agent extrapolation. Persistent challenges include separating direct neuroprotection from indirect metabolic and cardiovascular benefit, limited characterization of brain drug exposure, trial durations that may be short relative to the expected latency of a disease-modifying effect, and the absence of validated response biomarkers. We conclude that although the mechanistic and epidemiological rationale for GLP-1 RAs in neurodegeneration remains biologically plausible, current trial evidence does not yet support their use outside clinical trials, irrespective of comorbid diabetes status; future studies should prioritize earlier intervention, biomarker-guided patient selection, adequately powered subgroup analyses, and brain-penetrant formulations.
Frontiers in Aging Neuroscience · vol. 18 · 1742343-1742343
Background: Sleep is a fundamental biological process essential for maintaining mental, emotional, and physical health. Chronic sleep deprivation (SD), particularly in aging, is associated with oxidative stress, neuroinflammation, apoptosis, and cognitive and behavioral impairments. Oxytocin, a hypothalamic neuropeptide with reported antioxidant and anti-inflammatory properties, may modulate stress-related pathways; however, its role in mitigating SD-induced brain alterations remains unclear. This study investigated whether peripheral oxytocin administration influences brain and behavioral changes induced by chronic SD in aged rats. Methods: Male Sprague Dawley rats aged 20-24 months were divided into four groups: control, oxytocin-treated, SD, and SD with oxytocin treatment. Chronic SD was induced using a modified multiple platform method. Behavioral assessments were conducted to evaluate locomotor and exploratory activity. Serum cortisol was measured as a systemic stress marker, while brain tissues were analyzed for oxidative stress and inflammatory markers. Gene expression of Psen1 and Htr2a, oxytocin receptor protein levels, and histopathological changes, including gliosis and apoptosis, were also evaluated. Results: Chronic SD resulted in significant impairments in locomotor and exploratory behaviors, elevated serum cortisol levels, and increased oxidative stress and inflammatory markers. SD also altered the expression of Psen1 and Htr2a, reduced oxytocin receptor protein levels, and was associated with histological evidence of gliosis and apoptosis in brain tissues. Peripheral oxytocin administration attenuated many of these SD-induced alterations. However, because oxytocin was administered peripherally and central oxytocin levels or receptor engagement were not directly assessed, the findings cannot be interpreted as definitive evidence of direct central neuroprotection. Conclusion: The results suggest that oxytocin modulates stress responses, oxidative balance, and inflammatory pathways in aged rats subjected to chronic sleep deprivation. Although the precise central mechanisms remain unresolved, these findings support a potential role for oxytocin in mitigating SD-associated pathophysiological changes in aging and warrant further mechanistic studies to clarify its neuroprotective potential.
= 1.79 ± 0.05 µM), supporting its targeted anti-angiogenic mechanism. Flow cytometry analysis showed that 7e induced G0/G1 cell cycle arrest and markedly increased apoptotic cell populations. This was further confirmed by upregulation of Bax, Caspase-3, and Caspase-8, alongside downregulation of Bcl-2, indicating activation of both intrinsic and extrinsic apoptotic pathways. Interestingly, 7e inhibited cancer cell migration, suggesting a potential anti-angiogenetic effect. Density functional theory (DFT) calculations revealed that 7e possesses a conjugated electronic system with a suitable frontier orbital distribution, moderate HOMO-LUMO gap, and a favorable electrostatic potential for receptor interaction. Molecular docking and dynamics simulations demonstrated stable binding of 7e within the VEGFR-2 active site, supported by consistent RMSD, hydrogen bonding, and compact structural behavior. MM-GBSA calculations confirmed favorable binding free energy, while per-residue decomposition and protein-ligand interaction fingerprint analysis identified key stabilizing interactions. Essential dynamics and free energy landscape mapping further confirmed a stable and energetically favorable conformational state. ADMET and toxicity predictions indicated acceptable pharmacokinetic properties, low mutagenic risk, and an overall favorable safety profile. Collectively, these findings identify compound 7e as a promising VEGFR-2-targeted anticancer lead with strong enzymatic inhibition, potent cytotoxicity, and a well-supported mechanistic profile integrating experimental and computational evidence.
BackgroundThe increasing use of anti-diabetic drugs, particularly glucagon-like peptide-1 receptor agonists (GLP-1 RAs), for weight loss has prompted concerns about public awareness, attitudes, and usage.In Saudi Arabia, a substantial proportion of adults have obesity or are overweight, highlighting the considerable burden of obesity.Meanwhile, the increasing use of GLP-1 RAs for weight management underscores the importance of assessing public knowledge and attitudes toward these medications. ObjectiveThe objective of this study is to assess knowledge, attitudes, and practices regarding antidiabetic medications used for weight loss among adult residents of Riyadh, Saudi Arabia. MethodsThe cross-sectional survey included 282 adult residents of Riyadh.A self-administered electronic questionnaire was sent using a non-probability convenience sampling method.The questionnaire evaluated sociodemographic variables, knowledge, attitudes, and practices about antidiabetic medicines used for weight loss.Data were analyzed using nonparametric tests, Spearman's ρ correlation, and multivariable linear and binary logistic regression analyses. ResultsOf the 282 participants, 70.9% were female and 68.4% were married.The median knowledge score was 15.0 (interquartile range (IQR), 12.0-18.0),and the median attitude score was 23.0 (IQR, 21.0-25.0).Knowledge and attitude scores showed a weak positive correlation (Spearman's ρ = 0.254, p < 0.001).Overall, 76 participants (27.0%) reported using antidiabetic medications for weight reduction, with Ozempic (55.3%) and Mounjaro (44.7%) being the most commonly used medications.Female gender was independently associated with higher knowledge scores, whereas non-medical occupation was associated with lower knowledge and attitude scores.Participants with chronic disease had higher odds of weight-loss medication use, whereas higher attitude scores were associated with lower odds of use. ConclusionAdults in Riyadh demonstrated important knowledge gaps regarding weight-loss medications.Knowledge and attitudes varied by occupation, while medication use was independently associated with chronic disease status and attitude scores, highlighting the need for evidence-based education and medically supervised use.
Tavapadon is an oral, once-daily, non-catechol partial agonist selective for the D1 and D5 dopamine receptors and represents a mechanistically distinct option currently under clinical investigation for Parkinson disease (PD). This narrative review critically evaluates the biological rationale for D1/D5 receptor targeting, the pharmacological and preclinical development of tavapadon, and the accumulating phase 1–3 clinical evidence for its use as monotherapy in early PD and as adjunctive therapy in patients with motor fluctuations, while highlighting remaining evidence gaps and methodological limitations. A non-systematic literature search of PubMed/MEDLINE, Embase, ClinicalTrials.gov , and Scopus (through May 2026) was performed to identify representative and pivotal randomized controlled trials, pharmacokinetic/pharmacodynamic studies, and mechanistic preclinical investigations relevant to tavapadon and D1/D5 receptor agonism; this narrative approach was not intended to be exhaustive or fully reproducible in the manner of a systematic review. Mechanistically, selective stimulation of the direct striatal pathway together with submaximal intrinsic efficacy at the D1 receptor has been proposed, as a mechanistic hypothesis rather than a demonstrated clinical mechanism, to preserve antiparkinsonian benefit while limiting the receptor-signaling intensity implicated in levodopa-induced dyskinesia. In the phase 2 PARKWAY-II study and the now fully published phase 3 TEMPO-1 and TEMPO-2 trials, fixed- and flexible-dose tavapadon produced clinically meaningful improvements in MDS-UPDRS motor scores compared with placebo in early PD, and in the phase 3 TEMPO-3 trial, adjunctive tavapadon significantly increased daily good ON time and reduced OFF time in levodopa-treated patients with motor fluctuations; efficacy in all trials has been demonstrated only against placebo, with no head-to-head data against levodopa or other dopamine agonists. Adverse events were more frequent with tavapadon than placebo (approximately 72–76% versus 55% across TEMPO-2 and TEMPO-3), with nausea, headache, and dizziness the most common; no excess signal of impulse-control disorders relative to placebo was detected over the available 26–27-week controlled treatment period, and no clinically significant QTc prolongation was observed. The 58-week open-label TEMPO-4 extension, now reported in a peer-reviewed AAN abstract publication in Neurology alongside earlier interim conference data, suggests sustained benefit and a stable long-term levodopa requirement, but lacks a randomized control and cannot yet establish long-term safety superiority over existing agents. Tavapadon is a mechanistically novel candidate with preliminary evidence of efficacy; its ultimate clinical utility will depend on head-to-head trials and long-term safety data.
Organophosphorus pesticides (OPPs) are widely used and have recently been linked to metabolic syndrome (MS). This study aimed to investigate the probable association between chronic OPP exposure and MS among farm workers in Sharkia Governorate, Egypt, and to assess the potential role of peroxisome proliferator-activated receptor gamma (PPARγ). This comparative cross-sectional study included 140 participants, equally divided into OPP-exposed farm workers and non-exposed subjects. OPP exposure was confirmed by detecting plasma residues and cholinesterase activity. MS was diagnosed by assessing body mass index (BMI), waist circumference (WC), blood pressure, plasma glucose, serum insulin, and lipid parameters. Oxidative and inflammatory markers, including malondialdehyde (MDA), gamma-glutamyl transferase (GGT), ferritin, superoxide dismutase (SOD), tumor necrosis factor-alpha (TNF-α), and high-sensitivity C-reactive protein (hs-CRP), were measured. The mRNA expression of the PPARγ and paraoxonase 1 (PON1) genes was also investigated. In total, 60% of farm workers demonstrated MS, compared with 10% of non-exposed participants. Workers exhibited elevated oxidative and inflammatory indices and reduced PPARγ and PON1 expression. PPARγ positively correlated with high-density lipoprotein (HDL), SOD, and PON1, while negatively correlating with glucose, insulin resistance (IR), low-density lipoprotein (LDL), triglycerides (TGs), MDA, GGT, ferritin, TNF-α, and hs-CRP. The study concluded that chronic OPP exposure was associated with increased oxidative stress and inflammation, reduced PPARγ and PON1 expression, disturbed glucose and lipid metabolism, and increased IR. The observed associations between PPARγ downregulation, metabolic disturbances, and oxidative and inflammatory markers suggest that PPARγ dysregulation may represent a potential mechanistic link between chronic OPP exposure and MS. However, this proposed mechanism requires further validation.
Archiv der Pharmazie · vol. 359 (9) · e70328-e70328
ABSTRACT A new series of chromene derivatives ( 12–19 ) was rationally designed as potential inhibitors of vascular endothelial growth factor receptor‐2 (VEGFR‐2) by integrating essential pharmacophoric and structural features. The target compounds were synthesized and structurally confirmed using spectroscopic techniques. Their in vitro antiproliferative activities were evaluated against a panel of human cancer cell lines (MCF‐7, MDA‐MB‐231, HepG‐2, and HCT‐116) alongside normal human cells (WI‐38 and WISH), in addition to a VEGFR‐2 enzyme inhibition assay. Among the synthesized derivatives, compound 17 emerged as the most potent candidate, displaying low micromolar IC 50 values across all tested cancer cell lines and superior VEGFR‐2 inhibitory activity (IC 50 = 0.518 µM) compared with the reference drug sorafenib (IC 50 = 0.809 µM). Mechanistic investigations revealed that compound 17 induced pronounced cell cycle arrest and triggered apoptosis, as demonstrated by Annexin V–FITC/PI flow cytometric analysis. Computationally, Density Functional Theory (DFT) calculations demonstrated favorable electronic properties for compound 17, supporting effective ligand–receptor interactions. Molecular docking and 100‐ns molecular dynamics (MD) simulations, complemented by MM‐GBSA binding free energy calculations, Protein–Ligand Interaction Fingerprinting (Pro‐LIF), Principal Component Analysis (PCA‐T), and Free Energy Landscape (FEL) analyses, confirmed the stability and favorable binding energetics of compound 17 within the VEGFR‐2 active site. Furthermore, in silico ADME–Tox profiling predicted acceptable pharmacokinetic behavior and a favorable safety profile. Collectively, these experimental and computational findings identify compound 17 as a promising and mechanistically well‐characterized VEGFR‐2 inhibitor, warranting further in vivo investigation.
Frontiers in Pharmacology · vol. 17 · 1826774-1826774
Introduction: Myelotoxicity is a common adverse effect of vincristine and other chemotherapeutic drugs. Hesperetin is a bioactive flavanone with anti-inflammatory activity. This study was planned to examine the hesperetin protecting effect against vincristine induced myelosuppression and splenic inflammation in mice and test whether this effect is mediated through the suppression of Toll-like receptor 4 (TLR4)/myeloid differentiation primary response-88 (MYD88)/nuclear factor-kappa B (NF-κB) signaling pathways. Methods: Bioinformatics tools were used to establish the rationale of the study and molecular docking defined the potential binding of hesperetin to TLR4. Mice were allocated into different experimental groups: Group 1: was the saline mice, Group 2; mice were injected with vincristine (0.1 mg/kg, i. p) for 5 days per week, Group 3; mice received vincristine (as in Group 2) plus hesperetin (100 mg/kg, p. o.) and Group 4; mice received hesperetin (100 mg/kg, p. o.) only; the experiment continued for 2 weeks. Results: 9/L in the saline group, p less than 0.05) and bone marrow hypocellularity (dropped to ∼30-40% compared to 95%-100% in the saline group). The spleens showed white pulp lymphoid depletion, red pulp mild hypocellularity, greater immunostaining for MYD88, and greater content for TLR4, NF-κB, MYD88, TNF-α and IL-1β proteins. Results of molecular docking showed that hesperetin is an interesting complementarity with the TLR4/MD2 interface which was a good rationale for the experimental validation. The mouse experiment showed that hesperetin prevented the decrease hematological parameters, enhanced the bone marrow cellularity to 80%-90%, and the splenic architecture. Hesperetin further inhibited the increases in the target proteins (TLR4, NF-κB, MYD88, TNF-α and IL-1β) significantly. Discussion: The present data documents the novel role of hesperetin in mitigating myelotoxicity of vincristine through modulation of TLR4/MYD88/NF-κB signaling and a direct binding to TLR4 was proposed by molecular docking. This highlights possible usefulness of this combination after adequate clinical studies.
Journal of Computational Biophysics and Chemistry · 1-20
The development of selective vascular endothelial growth factor receptor-2 (VEGFR-2) inhibitors remains a promising strategy for anticancer therapy targeting tumor angiogenesis. In the study at hand, a novel benzanilide-based derivative, ACEB-Cl, was rationally designed by assimilating fundamental pharmacophoric characteristics essential for VEGFR-2 inhibition. ACEB-Cl was evaluated using a comprehensive approach that combined computational modeling, synthesis, and in vitro biological assessment. Density functional theory (DFT) calculations revealed a favorable electronic profile, with distinct nucleophilic and electrophilic regions that could support potential interactions within the VEGFR-2 binding pocket. Docking and molecular dynamics (MD) simulations suggested stable binding of ACEB-Cl within the ATP-binding pocket, supported by strong hydrophobic interactions and favorable binding free energy ([Formula: see text] kcal/mol). Following synthesis, ACEB-Cl confirmed potent anti-VEGFR-2 activity in an ELISA-based assay (IC[Formula: see text]M), showing higher potency than sorafenib. Western blot analysis further confirmed significant downregulation of phosphorylated VEGFR-2 in MDA-MB-231 cells. In vitro cytotoxicity studies revealed selective anticancer activity, with reduced toxicity toward normal Vero cells and favorable selectivity indices. Mechanistically, ACEB-Cl triggered G0/G1 phase arrest and significantly increased apoptotic cell death, highlighting its ability to suppress cancer cell proliferation. Additionally, ADMET and toxicity estimations indicated a balanced pharmacokinetic and safety profile, with improved solubility, acceptable absorption, and reduced toxicity risks compared to sorafenib. Overall, this integrated study pinpointed ACEB-Cl as a promising VEGFR-2-targeted anticancer lead compound with strong inhibitory potency and a clearly defined mechanism of action, supporting its progression for further improvement.
VEGFR-2 inhibitorsbenzanilidestumor angiogenesisanticancer drug discovery
Journal of Computational Biophysics and Chemistry · 1-20
The pursuit of selective vascular endothelial growth factor receptor-2 (VEGFR-2) inhibitors continues to be a key approach in anticancer drug discovery. In this context, a new benzanilide-based derivative, Z-CMPBC, was designed following essential VEGFR-2 pharmacophoric requirements and investigated through combined computational and biological approaches. Density functional theory (DFT) calculations at the B3LYP/6-31[Formula: see text]G(d, p) level indicated favorable electronic characteristics, including balanced chemical hardness and pronounced electrophilicity, suggesting a strong propensity for interaction within kinase active sites. Molecular docking, supported by 200 ns molecular dynamics simulations, demonstrated stable accommodation of the compound within the VEGFR-2 binding pocket. Binding free energy calculations using the MM-GBSA method revealed a significant interaction profile ([Formula: see text] kcal/mol), mainly governed by van der Waals forces and persistent hydrophobic interactions with critical residues. Biological assessment confirmed potent VEGFR-2 inhibition, with an IC[Formula: see text] value of [Formula: see text]M, closely comparable to sorafenib ([Formula: see text]M). Western blot analysis further verified a reduction in phosphorylated VEGFR-2 (pY1054/Y1059) levels in MCF-7 cells, supporting effective intracellular kinase inhibition. Additionally, Z-CMPBC exhibited pronounced cytotoxicity, particularly against MCF-7 breast cancer cells (IC[Formula: see text]M), along with a high selectivity index ([Formula: see text]) relative to normal Vero cells. Flow cytometry analysis demonstrated induction of G0/G1 phase arrest, accompanied by enhanced apoptotic activity (34.05%) compared to untreated cells. In silico ADMET and toxicity predictions suggested acceptable pharmacokinetic behavior and safety characteristics. Overall, these findings highlight Z-CMPBC as a promising VEGFR-2 inhibitor with potential for further development as an anticancer agent.
VEGFR-2 inhibitorsanticancer drug discoverykinase inhibitorsMCF-7 cells
Journal of King Saud University - Science · vol. 38 · 3852025-3852025
Lung cancer is the leading cause of cancer-related death in numerous countries worldwide. Given their severe side effects that can impact the patients’ quality of life, the current treatment approaches need more specific targeting to reduce chemotherapeutic toxicities. Cell-based targeted delivery has recently gained momentum as a promising platform for the delivery of anticancer drugs. As a new biotechnology platform, bacterial ghosts (BGs) have novel biomedical applications, including targeted drug delivery systems. In the current work, the BG of Streptococcus pneumoniae and Klebsiella pneumoniae ghosts were used as potential targeted-delivery agents for treating lung cancer cells. Bacterial ghosts of S. pneumoniae and K. pneumoniae were prepared using the most recent protocol (tween/acid). The doxorubicin (DOX) uploading was optimized by applying the required conditions to maximize loading capacity. We evaluated the DOX-loaded BGs’ antiproliferative and apoptotic effects on two lung cancer cell lines (H69A, A549) and one normal human embryonic kidney cell line (HEK293) in comparison to free BGs and DOX alone. We also tested the sustained release patterns for each formula. We predicted the mechanism of augmenting the actions of both systems by a protein-protein docking study. The preparation of well-formulated ghosts of both bacteria was successful and confirmed. The loading capacity was maximized to 31.2 ± 3.1% (n=3) for S. pneumoniae ghosts (SPG) and 28.8± 2.6% (n=3) for K. pneumoniae ghosts (KPG). The sustained release pattern of both SPG and KPG followed the Higuchi kinetic model, while Free DOX exhibited a rapid release pattern consistent with the first-order kinetic model. The antiproliferative activity using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) assay revealed the superiority of SPG loaded with DOX (SPG-DOX) over all other tested formulae (10.8% viability) on multi-drug-resistant lung cancer cells (H69A). The IC50s of SPG-Dox loaded were one-sixth and one-fifth of the IC50 of the Free DOX in H69A and A549, respectively, indicating more potency. The cell viability was 46.6% upon using Free DOX. In non-small cell lung cancer cells (A549), the SPG-DOX formula also showed superior antiproliferative activity (23.1% viability), as compared to control vehicles. SPG and KPG showed the highest safety toward the normal cell lines (HEK293), with more than 80% of cells surviving. Using H69A cells, KPG-DOX showed superior apoptotic activity (58.2%) over Free DOX, which achieved less than 20% cellular apoptosis. In A549 cells, SPG-DOX showed apoptotic activity of 57.7% compared to Free DOX. (32.5%). The docking study showed a strong binding interaction between a KPG surface protein (4HWM) and the overexpressed non-small cell lung cancer carcinoma receptor, epidermal growth factor receptor kinase domain (EGFR 2ITO), with a binding score (S) for the interaction of -63.94 kcal/mol. The interaction was -61.26 of SPG surface protein (3ZPP) with EGFR. The application of S. pneumoniae and K. pneumoniae BGs loaded with DOX represents a promising targeted drug delivery system for the treatment of lung cancer. The superior potency and safety of both systems warrant further investigation into their preclinical and clinical activities.
Background: Plaque psoriasis, which is a chronic immune-mediated inflammatory skin condition, significantly reduces patients' quality of life. The cytokine interleukin-23 (IL-23) is a pivotal factor in the development of psoriasis, and icotrokinra is a new oral IL-23 receptor antagonist that has shown potential effectiveness in clinical trials. The main goal of this systematic review and meta-analysis was to assess the effectiveness and safety of icotrokinra in adults and adolescents with moderate-to-severe plaque-type psoriasis. Methods: A comprehensive literature search in PubMed, ScienceDirect, and the Cochrane Library, conducted in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) standards, identified randomized controlled trials that evaluated daily oral icotrokinra 200 mg versus placebo. The primary outcomes were Psoriasis Area and Severity Index (PASI) 90, Investigator's Global Assessment (IGA) 0/1, and adverse events (AEs) at 16 weeks. Risk ratios with 95% confidence intervals were summed up through a random-effects model. Results: A total of five randomized controlled trials involving 2,755 participants were included. Icotrokinra showed a significant increase in PASI 90, IGA 0/1, IGA 0, and Psoriasis Symptoms and Signs Diary 0 responses compared to placebo. The overall frequency of AEs was similar in both groups, but the rate of treatment discontinuation due to AEs was lower with icotrokinra. Conclusions: Icotrokinra is an effective and well-tolerated oral treatment for moderate-to-severe plaque psoriasis with considerable clinical and patient-reported benefits.
INTRODUCTION: Epidermal Growth Factor Receptor (EGFR) is a well-established therapeutic target in cancer treatment. In this study, a novel N-phenylacetamide derivative of theobromine, designated as T-1-PA, was designed as a potential semisynthetic EGFR inhibitor. METHOD: The 3D structure, stability, and electronic reactivity of T-1-PA were determined using Density Functional Theory (DFT) analyses. Molecular docking, molecular dynamics (MD) simulations, Molecular Mechanics Generalized Born Surface Area (MM-GBSA), Protein-Ligand Interaction Profiler (PLIP), and Principal Component Analysis of Trajectories (PCAT) were employed to evaluate the binding affinity and inhibitory potential of T-1-PA against EGFR. Computational ADMET profiling was conducted to predict drug-likeness and safety. Subsequently, T-1-PA was semisynthesized and subjected to in vitro biological evaluation. RESULTS: Computational analyses demonstrated a strong binding affinity of T-1-PA to EGFR. The compound exhibited favorable ADMET properties. In vitro assays revealed potent EGFR inhibition with an IC₅₀ of 0.736 ± 0.005 μM. T-1-PA also inhibited the proliferation of HepG2 and MCF7 cancer cell lines with IC₅₀ values of 0.88 ± 0.01 μM and 1.13 ± 0.01 μM, respectively. Flow cytometry analysis indicated induction of apoptosis and G1 phase cell cycle arrest in HepG2 cells. Additionally, T-1-PA significantly impaired HepG2 cell migration and wound-healing capacity. DISCUSSION: The results validate the computational predictions and highlight the anticancer potential of T-1-PA through EGFR inhibition and antiproliferative activity. The compound's favorable pharmacokinetic and safety profiles further support its therapeutic promise. CONCLUSION: T-1-PA is a promising semisynthetic compound with selective antiproliferative activity mediated via EGFR inhibition. These findings encourage further preclinical investigation of T-1-PA as a novel candidate for EGFR-targeted cancer therapy.